These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16145253)

  • 1. Metabolic syndrome: is there a pathophysiological common denominator?
    Tataranni PA
    World Rev Nutr Diet; 2005; 94():75-83. PubMed ID: 16145253
    [No Abstract]   [Full Text] [Related]  

  • 2. Mediators of sympathetic activation in metabolic syndrome obesity.
    Straznicky NE; Eikelis N; Lambert EA; Esler MD
    Curr Hypertens Rep; 2008 Dec; 10(6):440-7. PubMed ID: 18959829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathobiology of metabolic syndrome X in obese and non-obese South Asian Indians: further discussion and some suggestions.
    Das UN
    Nutrition; 2003 Jun; 19(6):560-2. PubMed ID: 12781862
    [No Abstract]   [Full Text] [Related]  

  • 4. Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications.
    Lambert GW; Straznicky NE; Lambert EA; Dixon JB; Schlaich MP
    Pharmacol Ther; 2010 May; 126(2):159-72. PubMed ID: 20171982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metabolic syndrome with vascular risk and arterial hypertension].
    Wassermann AO; Grosso CP
    Medicina (B Aires); 1996; 56(2):183-94. PubMed ID: 8935572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome.
    Thorp AA; Schlaich MP
    J Diabetes Res; 2015; 2015():341583. PubMed ID: 26064978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can the metabolic syndrome be explained by a unifying concept?
    Hjemdahl P
    Lancet Diabetes Endocrinol; 2015 Feb; 3(2):96-8. PubMed ID: 25618291
    [No Abstract]   [Full Text] [Related]  

  • 8. Autonomic dysregulation and the metabolic syndrome: pathologic partners in an emerging global pandemic.
    Lopes HF; Egan BM
    Arq Bras Cardiol; 2006 Oct; 87(4):538-47. PubMed ID: 17128327
    [No Abstract]   [Full Text] [Related]  

  • 9. The sympathetic nervous system and the metabolic syndrome.
    Mancia G; Bousquet P; Elghozi JL; Esler M; Grassi G; Julius S; Reid J; Van Zwieten PA
    J Hypertens; 2007 May; 25(5):909-20. PubMed ID: 17414649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of sympathetic nervous system activity associate with complex plasma lipids in metabolic syndrome subjects.
    Nestel PJ; Khan AA; Straznicky NE; Mellett NA; Jayawardana K; Mundra PA; Lambert GW; Meikle PJ
    Atherosclerosis; 2017 Jan; 256():21-28. PubMed ID: 27940403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanisms of elevated blood pressure in obesity-related hypertension].
    Aoi W
    Nihon Rinsho; 1992 May; 50 Suppl():420-5. PubMed ID: 1512980
    [No Abstract]   [Full Text] [Related]  

  • 12. Sympathetic Nervous System, Hypertension, Obesity and Metabolic Syndrome.
    Seravalle G; Grassi G
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):175-9. PubMed ID: 26942609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comment to: Grassi G, Dell'oro R, Quarti-Trevano F et al (2005) neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 48:1359-1365.
    Clark MG
    Diabetologia; 2005 Dec; 48(12):2689-90. PubMed ID: 16270196
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of multielectrode renal denervation on elevated sympathetic nerve activity and insulin resistance in metabolic syndrome.
    Tsioufis C; Dimitriadis K; Kasiakogias A; Kalos T; Liatakis I; Koutra E; Nikolopoulou L; Kordalis A; Ella RO; Lau EO; Grassi G; Papademetriou V; Tousoulis D
    J Hypertens; 2017 May; 35(5):1100-1108. PubMed ID: 28106665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin resistance and hypertension--implications for treatment.
    Rutherford PA; Thomas TH; Wilkinson R
    Postgrad Med J; 1991 Oct; 67(792):869-75. PubMed ID: 1758796
    [No Abstract]   [Full Text] [Related]  

  • 16. Sodium and obesity in the pathogenesis of hypertension.
    Reisin E
    Am J Hypertens; 1990 Feb; 3(2):164-7. PubMed ID: 2155002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated sympathetic nerve activity: the link between low birth size and adult-onset metabolic syndrome?
    Hausberg M; Barenbrock M; Kosch M
    J Hypertens; 2004 Jun; 22(6):1087-9. PubMed ID: 15167440
    [No Abstract]   [Full Text] [Related]  

  • 18. [Obesity and insulin resistance--risk factors and parts of metabolic syndrome].
    Mel'nichenko GA; Pyshkina EA
    Ter Arkh; 2001; 73(12):5-8. PubMed ID: 11858109
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome.
    Straznicky NE; Grima MT; Sari CI; Eikelis N; Lambert GW; Nestel PJ; Karapanagiotidis S; Wong C; Richards K; Marusic P; Dixon JB; Schlaich MP; Lambert EA
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1701-7. PubMed ID: 24937541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al.
    Psaty BM; Lumley T; Furberg CD
    Diabetes Care; 2006 Jan; 29(1):177; author reply 177-8. PubMed ID: 16419355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.